Standard BioTools Inc. Restructuring Charges
Standard BioTools Inc. (LAB) reported Restructuring Charges of $2.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-08-05
- Standard BioTools Inc. restructuring charges for the quarter ending 2026-06-30 was $2.81M, a 62.83% increase year-over-year.
- Standard BioTools Inc. restructuring charges for the quarter ending 2026-03-31 was $3.08M, a 98.45% increase year-over-year.
- Standard BioTools Inc. restructuring charges for the quarter ending 2025-12-31 was $2.08M, a 1546.83% increase year-over-year.
- Standard BioTools Inc. restructuring charges for the quarter ending 2025-09-30 was $9.43M, a 302.73% increase year-over-year.
- Standard BioTools Inc. restructuring charges for fiscal 2025 was $14.78M, a 18.26% increase from fiscal 2024.
- Standard BioTools Inc. restructuring charges for fiscal 2024 was $12.50M, a 76.65% increase from fiscal 2023.
- Standard BioTools Inc. restructuring charges for fiscal 2023 was $7.08M, a 27.29% decline from fiscal 2022.
- Standard BioTools Inc. restructuring charges for fiscal 2022 was $9.73M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 3 month as first filed | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 9 month as first filed | Restructuring Charges 12 month | Restructuring Charges 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.81M 10-Q · filed 2026-08-05 | $5.89M 10-Q · filed 2026-08-05 | $7.97M derived: sum of 3 quarters · filed 2026-08-05 | $17.39M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $3.08M 10-Q · filed 2026-05-06 | $5.16M derived: sum of 2 quarters · filed 2026-05-06 | $14.58M derived: sum of 3 quarters · filed 2026-05-06 | $16.31M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $11.50M derived: sum of 2 quarters · filed 2026-03-16 | $13.23M derived: sum of 3 quarters · filed 2026-08-05 | $14.78M 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $9.43M 10-Q · filed 2025-11-04 | $11.15M derived: sum of 2 quarters · filed 2026-08-05 | $12.71M 10-Q · filed 2025-11-04 | $12.83M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $1.73M 10-Q · filed 2026-08-05 | $3.28M 10-Q · filed 2026-08-05 | $3.40M derived: sum of 3 quarters · filed 2026-08-05 | $5.75M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $1.55M 10-Q · filed 2026-05-06 | $1.68M derived: sum of 2 quarters · filed 2026-05-06 | $4.02M derived: sum of 3 quarters · filed 2026-05-06 | $9.77M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.47M derived: sum of 2 quarters · filed 2026-03-16 | $8.22M derived: sum of 3 quarters · filed 2026-03-16 | $12.50M 10-K · filed 2026-03-16 | |||
| 2024-09-30 | $2.34M 10-Q · filed 2025-11-04 | $8.09M derived: sum of 2 quarters · filed 2025-11-04 | $12.37M 10-Q · filed 2025-11-04 | $14.04M derived: sum of 4 quarters · filed 2026-03-16 | |||
| 2024-06-30 | $5.75M 10-Q · filed 2025-08-15 | $10.03M 10-Q · filed 2025-08-15 | $11.69M derived: sum of 3 quarters · filed 2026-03-16 | $13.69M derived: sum of 4 quarters · filed 2026-03-16 | |||
| 2024-03-31 | $4.28M 10-Q · filed 2025-05-06 | $5.95M derived: sum of 2 quarters · filed 2026-03-16 | $7.94M derived: sum of 3 quarters · filed 2026-03-16 | $10.21M derived: sum of 4 quarters · filed 2026-03-16 | |||
| 2023-12-31 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $3.66M derived: sum of 2 quarters · filed 2026-03-16 | $5.93M derived: sum of 3 quarters · filed 2026-03-16 | $7.08M 10-K · filed 2026-03-16 | |||
| 2023-09-30 | $2.00M 10-Q · filed 2024-11-06 | $4.26M derived: sum of 2 quarters · filed 2024-11-06 | $5.42M 10-Q · filed 2024-11-06 | $10.04M derived: sum of 4 quarters · filed 2025-03-11 | |||
| 2023-06-30 | $2.27M 10-Q · filed 2024-08-06 | $3.42M 10-Q · filed 2024-08-06 | $8.05M derived: sum of 3 quarters · filed 2025-03-11 | $11.46M derived: sum of 4 quarters · filed 2025-03-11 | |||
| 2023-03-31 | $1.15M 10-Q · filed 2024-05-09 | $357.00K 10-Q · filed 2023-05-09 | $5.78M derived: sum of 2 quarters · filed 2025-03-11 | $9.19M derived: sum of 3 quarters · filed 2025-03-11 | $9.49M derived: sum of 4 quarters · filed 2025-03-11 | ||
| 2022-12-31 | $4.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $8.04M derived: sum of 2 quarters · filed 2025-03-11 | $8.34M derived: sum of 3 quarters · filed 2025-03-11 | $9.73M 10-K · filed 2025-03-11 | $5.41M 10-K · filed 2023-03-14 | ||
| 2022-09-30 | $3.41M 10-Q · filed 2023-11-07 | $2.25M 10-Q · filed 2022-11-09 | $3.71M derived: sum of 2 quarters · filed 2023-11-07 | $5.10M 10-Q · filed 2023-11-07 | $2.25M 10-Q · filed 2022-11-09 | ||
| 2022-06-30 | $300.00K 10-Q · filed 2023-08-08 | $1.69M 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |